Introduction {#s1}
============

The type 1A and 1B melatonin receptors (MT~1~ and MT~2~) are G protein-coupled receptors (GPCRs) that respond to the neurohormone melatonin (N-acetyl-5-methoxytryptamine) ([@bib39]; [@bib40]). Melatonin is found in all mammals, including humans, where it regulates sleep and helps to synchronize the circadian rhythm with natural light-dark cycles ([@bib10]; [@bib48]). Chemically, melatonin is synthesized from serotonin in the pineal gland of the brain during darkness ([@bib18]). Both MT~1~ and MT~2~ share canonical helical 7-transmembrane (7-TM) topology ([@bib25]; [@bib42]), although they are differentially expressed and implicated in diverse biological functions and pathologies ([@bib15]). While exogenous melatonin has been commonly used for the treatment of insomnia and jetlag, more effective and long-lasting MT agonists such as ramelteon have been approved for primary chronic insomnia treatment, because of their low side-effect profile as compared to other sleeping aids such as benzodiazepines ([@bib21]; [@bib16]). Other MT agonists such as tasimelteon and agomelatine, are used for non-24-hour sleep-wake disorders in blind individuals and as an atypical anti-depressant for major depressive disorders, respectively ([@bib35]; [@bib14]). Recent studies also suggest MT receptors play an essential role in learning, memory, and neuroprotection ([@bib36]) and illustrate the potential utility of partial and selective MT~2~ receptor agonists as antinociceptive drugs ([@bib37]). Moreover, MT~2 ~single nucleotide polymorphisms (SNPs) are implicated in type-2 diabetes ([@bib26]) (T2D), emphasizing the importance of MT receptors in a wide variety of functions relevant to human health and the quality of life ([@bib27]).

Although MT~1~ and MT~2~ receptors have distinctive in vivo functions, most of the currently available drugs non-selectively activate both MT~1~ and MT~2~ receptors ([@bib51]).Recent studies on melatonin receptors using partially selective MT~2~ ligands and gene knockout approaches have shed light on difference in the biology of melatonin receptor subtypes. For example, the MT~2~ receptor regulates non-rapid eye movement (NREM) while MT~1~ mediates rapid eye movement (REM) phases of the vigilance state in sleep architecture ([@bib12]; [@bib17]; [@bib36]). The discovery of novel and selective MT ligands may, therefore, lead to useful tool compounds for better pharmacological dissection of the melatonin system, and accelerate the development of alternatives to existing drugs ([@bib24]; [@bib50]).

Recently, the three-dimensional structures of MT~1~ and MT~2~ were determined using an X-ray free-electron laser (XFEL), providing atomic-level details of receptor-ligand interactions ([@bib25]; [@bib42]). Although both receptors were resolved in complexes with agonists -- agomelatine, 2-phenylmelatonin, 2-iodomelatonin and ramelteon, thermostabilizing mutations that were necessary for crystallization rendered these receptors functionally inactive. Therefore, the accuracy of these agonist-bound inactive structures in reproducing the active-state conformation of the orthosteric pocket, and their utility in the prospective discovery of new agonists requires further validation.

Here, we utilized the MT structural information to perform a large scale virtual ligand screen (VLS) on both MT~1~ and MT~2~ receptors, using libraries of 8.4 million available-for-purchase fragment-like and lead-like compounds ([@bib44]). Subsequent experimental testing of 62 compounds selected from the top scoring molecules led to the discovery of ten new agonist chemotypes with sub-micromolar potencies, with one of them, compound **21**, displaying sub-nM agonist potency (EC~50~ = 0.36 nM) in G-protein assays. Six of these hits, including the most potent one, demonstrated selectivity for MT~2~, while five hits were partial agonists at MT~2~. Moreover, the two most potent MT~2~ compounds, **21** and a close derivative of melatonin, **28**, show reduced arrestin signaling, thus resulting in substantial bias towards G-protein signaling. Our results demonstrate that structure-based VLS approach can yield novel, highly potent and selective ligand chemotypes with potential utility as chemical probes with distinct properties and candidate leads for the treatment of circadian rhythm related sleep and mood disorders.

Results {#s2}
=======

Benchmarking receptor models {#s2-1}
----------------------------

To evaluate the ability of the structure-based receptor models to recognize high-affinity melatonin receptor ligands, we performed extensive docking of a subset of known ligands of MT~1~ and MT~2~ receptors ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) into (i) the unmodified 3D structures obtained from X-ray crystallography (MT~1~\_Xtal, MT~2~\_Xtal), as well as (ii) into the receptor models where the ligand-binding pocket was optimized by conformational modeling (MT~1~\_Opt, MT~2~\_Opt). Analysis of the docking poses for the known MT ligands in both crystal structures and optimized MT receptor models showed favorable binding scores with docking poses consistent with the orientation and binding modes of crystallized ligands ([Figure 1a--d](#fig1){ref-type="fig"}). The major interactions include aromatic stacking of the heterocyclic core with ECL2 hydrophobic residue F179/192*^ECL2^* (the residue numbers for MT~1~ and MT~2~ listed for UniProt ([@bib8]) ids: P48039 and P49286, respectively, followed by superscripted Ballesteros -- Weinstein numbering scheme [@bib7]), as well as hydrogen bonding interactions with N162/175*^4.60^* and Q181/194*^ECL2^* ([@bib25]; [@bib42]) . The performance of each model was then evaluated as the area under the corresponding receiver operator characteristic (ROC) curve (AUC), benchmarking the ability of these models to correctly detect ligands among decoys. The AUC values for the optimized models of MT receptors showed substantial improvement over AUC values for MT crystal structures (MT~1~\_Opt = 87 vs. MT~1~\_Xtal = 69; and MT~2~\_Opt = 82 vs. MT~2~\_Xtal = 70) (see [Figure 1e](#fig1){ref-type="fig"}). Overall, these results validated the improved VLS performance of the optimized models of MT~1~ and MT~2~ receptors, which were then used for large-scale prospective VLS.

![Predicted binding modes of selected known MT ligands.\
(**a**) 5-HEAT and (**b**) S-26131 docked into MT~1~\_Opt model; whereas (**c**) IIK-7 and (**d**) 4P-PDOT docked into MT~2~\_Opt model. (**e**) ROC plots for MT receptor crystal structures and optimized models.](elife-53779-fig1){#fig1}

Prospective VLS and candidate selection {#s2-2}
---------------------------------------

A library of 8.4 million commercially available compounds was docked into the optimized MT~1~\_Opt and MT~2~\_Opt structural models (see Materials and methods), and for every compound, docking scores and binding interactions were predicted. The top 5000 scoring compounds were selected from these VLS runs for each receptor, which were further evaluated by redocking into both MT~1~ and MT~2~ receptors with increased computational sampling. The initial hit list contained 700 compounds predicted to bind to both receptors. To evaluate these top docking solutions, we created additional models of MT receptors by restoring thermostabilizing mutations ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) in the proximity of the orthosteric site to wild-type residues (A104*^3.29^*G and W251*^6.48^*F in MT~1~; W264*^6.48^*F in MT~2~), and performed further conformational optimizations. We determined that the impact of these mutations on the docking results was negligible. The dock scores for selected MT ligands were better than the standard ICM VLS cutoff −32.0 kJ/mol, which is better than or comparable to the docking score of melatonin (−29.3) and other high affinity MT receptor ligands ([@bib25]).

To capture chemotype diversity, we selected the top 500 compounds for each receptor using chemical clustering in combination with docking scores. A final set of 62 compounds (23 from only MT~1~ VLS; 25 from only MT~2~ VLS; 14 from both MT~1~ and MT~2~ VLS) were selected for purchase based on a multidimensional composite criterion accounting for compound novelty, chemical diversity, well-defined interaction patterns with binding site residues N162/175*^4.60^* and/or Q181/194*^ECL2^*, and interaction similarities with ligands observed in the crystal structures (See [Figure 2](#fig2){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"} Table S1).

![Structural features in selected hit candidate compounds.\
(**a**) 2-phenylmelatonin in complex with MT1 receptor with the topology of chemical features shown as colored spheres indicating R1 (orange) = 5-methoxy, R2 (green) = alkylamido chain, and R3 (blue) = 2-phenyl substitutions, (**b**) Venn diagram summarizing the topologically equivalent chemical features in selected 62 candidate compounds from MT~1~ and MT~2~ VLS.](elife-53779-fig2){#fig2}

Most of the compounds represented new chemotypes with Tanimoto chemical distance values \>0.22 ([@bib2]), separating them from known high-affinity MT ligands available in CHEMBL24 ([@bib20]). We also chose a close analog of melatonin -- compound **28** (Tanimoto distance = 0.05), which to our knowledge, has not yet been characterized as a ligand for MT receptors ([@bib20]; [@bib32]). Compound **28** served as an additional positive control, which also helped us to evaluate the effect of a single chemical group substitution in melatonin on the binding and function at the MT receptors.

Experimental hit identification and validation {#s2-3}
----------------------------------------------

The selected 62 candidate compounds from VLS were tested experimentally for binding and functional profiles in both MT receptors. Eleven compounds ([Table 1](#table1){ref-type="table"}; [Figure 3](#fig3){ref-type="fig"}) demonstrated sub-micromolar potencies in G~i/o~ mediated signaling assays (18% hit rate). Ten of these eleven compounds also showed binding affinities K~i~ \<10 µM in a competition binding assay ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The melatonin derivative **28** identified by VLS was as potent as melatonin itself in MT~2~ (EC~50~ = 0.04 nM) and had the same potency (EC~50~ = 0.04 nM) at MT~1~. The most potent new chemotype, **21,** displayed an EC~50~ = 0.36 nM for MT~2~, with a 30-fold selectivity over MT~1~ receptor (MT~1~EC~50~ = 12 nM). Overall, seven hits had EC~50~ \<100 nM for at least one of the melatonin receptors. Similar to other low molecular weight MT ligands, most of the hits identified belong to a library of fragment-like compounds with molecular weights less than 250 Da, and have exceptionally high ligand efficiency (LE), far exceeding the \~0.3 value considered as a standard for a promising lead. For example, compound **21** (Mol. Wt. = 224 Da) had the highest LE values of 0.83 kcal/mol per non-hydrogen atom for MT~2~ and 0.69 kcal/mol per non-hydrogen atom for MT~1~ receptors ([@bib22]; [@bib23]). The excellent LE of these molecules allows the potential for further optimization of their drug-like properties.

###### Hit compounds from VLS with G~i/o~ mediated potency EC~50~ \<1 µM for at least one MT receptor.

                  MT~1~         MT~2~          MT~2~/MT~1~                                                                                                    
  --------------- ------------- -------------- ------------- ------------- ------ ------------- -------------- ----------- -------------- ------ ------------ ------
  **21**          6.31 ± 0.11   7.91 ± 0.05    **12.0**      93.8 ± 2.5    0.69   6.91 ± 0.05   9.44 ± 0.08    **0.36**    86.1 ± 3.2     0.83   30.6         0.50
  **23**          5.42 ± 0.03   7.16 ± 0.09    **57.5**      96.9 ± 5.3    0.56   5.56 ± 0.13   7.69 ± 0.08    **20.42**   91.7 ± 3.0     0.60   2.7          0.22
  **28**          7.78 ± 0.10   10.39 ± 0.04   **0.04**      95.3 ± 2.6    0.86   7.63 ± 0.08   10.35 ± 0.10   **0.04**    *69.4 ± 4.0*   0.85   [0.7]{.ul}   0.05
  **29**          5.22 ± 0.07   6.83 ± 0.06    144.5         87.5 ± 4.5    0.53   5.61 ± 0.05   7.46 ± 0.10    **34.67**   *69.4 ± 8.0*   0.58   3.3          0.43
  **37**          5.07 ± 0.13   ND             \>30000       ND            ND     5.45 ± 0.10   6.85 ± 0.19    141.25      *61.1 ± 9.1*   0.53   \>1000.0     0.57
  **44**          4.19 ± 0.36   3.33 ± 0.36    57544.0       72.8 ± 4.7    0.33   4.95 ± 0.30   6.58 ± 0.13    263.03      88.9 ± 6.3     0.51   267.2        0.59
  **45**          4.54 ± 0.15   5.06 ± 0.12    8709.6        90.6 ± 14.3   0.44   5.26 ± 0.19   6.37 ± 0.13    426.58      75.0 ± 7.4     0.56   16.9         0.59
  **47**          4.58 ± 0.07   5.25 ± 0.16    2344.2        112.4 ± 5.2   0.46   5.91 ± 0.12   7.99 ± 0.10    **10.23**   91.7 ± 3.0     0.66   186.9        0.60
  **54**          5.03 ± 0.06   6.06 ± 0.07    741.3         82.8 ± 4.3    0.54   5.56 ± 0.10   7.74 ± 0.10    **18.20**   75.0 ± 3.7     0.68   36.9         0.43
  **57**          4.84 ± 0.03   5.72 ± 0.11    1778.3        87.5 ± 9.1    0.47   5.37 ± 0.04   6.88 ± 0.15    131.83      *66.7 ± 8.3*   0.57   10.3         0.53
  **62**          4.32 ± 0.11   4.39 ± 0.42    42658.0       54.1 ± 10.0   0.36   5.49 ± 0.33   7.28 ± 0.14    **52.48**   *58.3 ± 4.8*   0.60   875.9        0.64
  **Melatonin**   9.06 ± 0.14   11.38 ± 0.06   **0.004**     100.0 ± 5.6   0.93   9.27 ± 0.14   10.30 ± 0.14   **0.05**    100.0 ± 5.6    0.84   [0.1]{.ul}   0.00

Standard error of the mean, N = 3.

^†^ Activation compared to melatonin.

 Ligand efficiency (based on EC~50~).

^§^Selectivity in folds (calculated as: Antilog (log(E~max~/EC~50~) MT~2~- log (E~max~/EC~50~) MT~1~)). MT~1~ selectivity is shown as underlined values.

^¶^ Tanimoto distance from closest MT receptor ligands in ChEMBL database with pAct \>6. Hits with EC~50~ \<100 nM are displayed in **bold**, and with E~max~ \<70% in italic.

![Functional characterization of selected VLS hits for agonist activity at MT~1~ and MT~2~ receptors in G~i/o~-mediated cAMP production inhibition assays.\
Results were normalized to the E~max~ value (%) of receptor activation by melatonin. These VLS hits showed no activity at control HEK293 T cells without transiently transfected MT~1~ or MT~2~ receptors (results not shown).](elife-53779-fig3){#fig3}

Chemical and conformational diversity of hits {#s2-4}
---------------------------------------------

Most of the hit compounds, as shown in [Chemical structure 1](#C1){ref-type="fig"}, are novel and display diverse chemotypes distinct from known high-affinity MT ligands (ChEMBL, pAct \>6.0), with Tanimoto distance exceeding 0.4 for all but two ligands (**28** and **23**). While the majority of known MT agonists reported in ChEMBL have either substituted indene or naphthalene core, only two of the eleven hits reported here have fused heterocycles and several others have two substituted aromatic rings connected by a flexible chain. Most compounds have diverse substitutions at positions topologically equivalent to the 5-methoxy, acetylamido and C2 position of melatonin ([Figure 2](#fig2){ref-type="fig"}). Two compounds\-- **21 **a**nd 29**\-- have a pyrimidine scaffold, whereas four compounds\-- **23**, **37**, **44**, and **57**\-- have a methoxyphenyl group in place of the 5-methoxy indole scaffold in melatonin. Another interesting core is the cyclopentyl-fused thienopyridine of compound **45**. Only 2 compounds, **28** and **54**, have substituted indoles similar to melatonin.

![Chemical structures of hit compounds with EC~50~ \<1 μM at the MT receptors.](elife-53779-fig8){#C1}

The predicted binding poses of the selected hit compounds in their docking models of MT receptors are shown in [Figure 4](#fig4){ref-type="fig"}. Nine out of eleven hits have methoxy or a similar group predicted to make hydrogen bonding interactions with N162/175*^4.60^*, which was found to be a critical residue for receptor activation, despite playing a limited role in ligand affinity or structural stability of the receptor ([@bib42]).

![Predicted binding poses for top six new chemotypes discovered with VLS.\
(**a**) **21**, (**b**) **23**, (**c**) **62**, (**d**) **29**, (**e**) **47** and (**f**) **54** inthe MT~2~receptor (purple). The center panel shows a canonical 7-TM receptor structure of MT~2~ receptor (blue helices; part of TM-V is not displayed for clarity) in complex with 2-phenylmelatonin shown as green spheres (PDB id: 6ME6).](elife-53779-fig4){#fig4}

Furthermore, seven of the hits were predicted to form hydrogen bonding interactions with Q181/194*^ECL2^* similar to alkylamide tail of melatonin. Five hits were predicted to occupy a significant space in the pocket flanked by TMs-II, III, and VII forming hydrophobic interactions, especially with residues Y281/294*^7.38^* and Y285/298*^7.43^*, as previously found in the MT receptor structures ([@bib25]; [@bib42]). These hydrophobic interactions are similar to those formed by the phenyl moiety of 2-phenylmelatonin. Both types of hydrogen bonding and hydrophobic interactions were found to be critical for a ligand's steric fit into the MT receptor binding pocket and are the primary determinants of ligand affinity.

Structural basis of subtype selectivity of the hits {#s2-5}
---------------------------------------------------

Six of the identified hits were found to be at least 30 fold more potent at MT~2~ compared to MT~1~ in the G~i/o-~mediated cAMP inhibition assays. Among the hits reported here with novel scaffolds, compound **21** has the highest potency for both MT~2~ (EC~50~ = 0.36 nM) and MT~1~ (EC~50~ = 12 nM). Compound **21** was predicted to bind both the MT receptors in a similar orientation by forming hydrogen bonding interactions with N162/175*^4.60^* and Q181/194*^ECL2^* with its methoxy anchor and acetylamido tail, respectively. These interactions had been reported to be critical for ligand affinity and potency at the MT receptors ([@bib25]; [@bib42]).

Other compounds also possess remarkable MT~2~ selectivity. For example, compound **47** is 187-fold selective towards MT~2~ (EC~50~ = 10 nM for MT~2~, and 2.34 µM for MT~1~, respectively). The pyrrole ring mimics the indole ring of melatonin, the amide group forms hydrogen bonding with N162/175*^4.60^* and the chlorophenyl group forms hydrophobic interactions with ECL2 and TM-II, III, and VII residues ([Figure 4](#fig4){ref-type="fig"}). Despite the lack of polar interactions with Q181/194*^ECL2^*, the compound displays sub-micromolar potency for MT~2~. Similarly, compound **45** also lacks a substitution topologically equivalent to acetylamido tail of melatonin (R2 feature) and yet has a sub-micromolar potency and 17-fold selectivity for MT~2~ (EC~50~ = 427 nM). In contrast, compound **44** was predicted to form interactions with Q181/194*^ECL2^,* but it lacks an R3 equivalent substitution, which still makes it 267-fold selective for MT~2~ (EC~50~ = 263 nM). These findings suggest that either R2 or R3 could be sufficient in maintaining the potency and selectivity at MT~2~.

Functional selectivity of the hit ligands {#s2-6}
-----------------------------------------

All the discovered hits show activity as agonists in G~i/o~-protein signaling assays at both MT~1~ and MT~2~ receptors. At the same time, some compounds show functional profiles notably distinct from full and balanced agonism, especially at MT~2~. Thus, four of the hits, **28**, **29**, **57**, and **62** had their efficacy (E~max~) reduced to less than 70% in MT~2~, and are therefore considered partial agonists ([@bib5]). The identified hits were also evaluated for their β-arrestin recruitment ([Figure 3---figure supplements 2](#fig3s2){ref-type="fig"} and [3](#fig3s3){ref-type="fig"}), with the comparative analysis of G-protein and β-arrestin activity shown in [Figure 5](#fig5){ref-type="fig"}. In the case of the MT~1~ receptor, there are no significant deviations from the overall balanced G-protein/Arrestin signaling profiles for most compounds ([Figure 5a](#fig5){ref-type="fig"}). One exception is compound **37,** which completely lacks G-protein signaling, though it still binds to MT~1~ and displays substantial β-arrestin activity. In the case of MT~2~, however, there are several compounds that show a marked reduction in β-arrestin signaling compared to G-protein, especially compounds **21** and **28**, which show bias factors of 15.5 and 33.9, respectively ([Figure 5b](#fig5){ref-type="fig"}). These results suggest that MT ligands may show rather distinct functional bias profiles in G-protein and β-arrestin signaling, as observed in many other GPCRs ([@bib31]; [@bib41]), though the biological importance of this bias in MT remains to be investigated ([@bib11]).

![Functional selectivity of selected VLS hits at MT~1~ (**a**) and MT~2~ (**b**) receptors.\
The pEC~50~ values of the ligands in G-Protein and Arrestin-mediated signaling assays are shown. The dashed lines for each receptor trace the melatonin datapoint to the origin, with compounds far above or below the line showing functional selectivity.](elife-53779-fig5){#fig5}

To gain more insights into these variations in ligand activity at MT receptors, we analyzed conformational differences among ligand-receptor pairs for these compounds. As the hit compounds are fragment--like and may attain multiple energetically-favorable poses at the orthosteric site upon docking, the specific conformational features driving partial agonism remain unclear. However, analysis of compounds **28** and **37** with the most pronounced bias to G-protein in MT~2~ and β-arrestin in MT~1~, respectively, suggests possible explanations for these phenomena.

Compound **28** is very similar to melatonin, except the amide is replaced by a urea. This substitution renders compound **28** as a partial agonist at MT~2~ (E~max~ = 69.4%) while largely maintaining full agonism at MT~1~ (E~max~ = 95.3%). Docking predictions suggest that compound **28** assumes an orientation in the binding pocket similar to 2-phenylmelatonin with subtle differences, as shown in [Figure 6](#fig6){ref-type="fig"}. In MT~2~ orthosteric site, the urea of compound **28** forms hydrogen bonding interactions with the side chains of polar residues Q194*^ECL2^* and N268*^6.52^* owing to its additional nitrogen. Such interactions, however, are energetically unfavorable in the case of MT~1~ with possible steric clashes ([@bib25]; [@bib42]). Instead, the interactions of acetylamido group of melatonin with Q181*^ECL2^* are replaced by a hydrogen bond between Y281*^7.38^* and oxygen from the urea in compound **28**. These interactions become favorable in MT~1~ as the residue Y281*^7.38^* is rotated towards TM-VI placing it 4 Å away from T178*^ECL2^*. In the case of MT~2~, however, residues Y294*^7.38^* -- T191*^ECL2^* are 3 Å apart forming an intermolecular hydrogen bond with Y281*^7.38^* oriented away from TM-VI allowing favorable orientation of Q194*^ECL2^* to form a hydrogen bond with compound **28**.

![Predicted binding poses for compounds **28** (**a, b**), and **37** (**c, d**) in MT~1~ (light green) and MT~2~ (lavender) receptors, respectively.\
The red dotted lines with arrows indicate a missing hydrogen bond between residues T178 and Y281 in MT~1~ receptor, while the yellow dots show hydrogen bonding interactions.](elife-53779-fig6){#fig6}

A similar pattern of ligand-receptor interaction is observed from the docking of the most selective compound **37** into MT receptors. Compound **37** has a distinct and much bulkier substitution with a 3-cyclopropyl-1,2,4-oxadiazol group (R2 feature). In MT~1~, this oxadiazol group is predicted to form hydrogen bonds with Q181*^ECL2^*, T178*^ECL2^* and Y281*^7.38^*, while the cyclopropyl group is predicted to fit in the sub pocket formed by ECL2, TM-V, and VII. These interaction pattern changes in MT~2~, where the prominent hydrogen bonding between side chains of T191*^ECL2^* and Y294*^7.38^* is formed, precluding hydrogen bonding of these residues to compound **37**. Moreover, the methoxy group (R1 feature) of the compound, which maintains a hydrogen bond with N175*^4.60^* in MT~2~ is lost with N162*^4.60^* side chain in MT1, due to a subtle shift of the compound. Indeed, the methoxy -- N162*^4.60^* interaction is found to be critical in receptor activation ([@bib42]), and loss of this interaction is likely to explain lack of activity of compound **37** in G~i~-mediated signaling at MT~1~. This interaction difference, however, does not seem to affect the β-arrestin mediated signaling by compound **37** in MT~1~. This peculiar feature of **37** is supported by our mutational studies, where N162Q mutation in MT~1~ actually increased potency of **37** slightly (2-fold), while Y281F, as expected, reduced potency by over 10x ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). For comparison, **28** drastically (\>100 fold) reduced potency in both MT~1~ mutants N162Q and Y281F. Taken together, these results support a key role of N162/175*^4.60^* anchoring interactions in G~i~-mediated receptor activation, and also suggest a distinct role of residues Y281/294*^7.38^* in governing ligand bias at MT receptors. Further analysis, including mutation and SAR studies of compound **37** derivatives are needed for comprehensive validation of this hypothetical mechanism in future studies.

Off-target profiling {#s2-7}
--------------------

To verify the ligand selectivity, the lead compounds **21**, **28**, and **37**, were subjected to binding profiling at a panel of 47 common drug targets (including many GPCRs and neurotransmitter transporters). At a final concentration of 10 μM, they did not show any substantial binding at these targets, except for compound **28** that displayed over 50% inhibition at three 5-HT receptors ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), with binding affinity of 851 nM (pK~i~ = 6.07 ± 0.11) for 5-HT~1A~, 1525 nM (pK~i~ = 5.82 ± 0.02) for 5-HT~1D~, and 286 nM (pK~i~ = 6.54 ± 0.03) for 5-HT~7A~. Assessment of functional activity of **28** in G~s~-mediated cAMP production shows that it is a weak partial agonist with EC~50~ = 1819 nM, as compared to 0.04 nM at both MT~1~ and MT~2~ receptors. These results demonstrated that the lead compounds **21**, **28**, and **37** act specifically at MT receptors and show high selectivity for MT~1~ or MT~2~ over many common drug targets.

Discussion {#s3}
==========

The discovery of potent and selective MT ligands with novel chemotypes holds promise for the development of next-generation drugs to treat circadian rhythm and mood disorders, pain, insomnia, type-2 diabetes, and cancer ([@bib27]; [@bib36]). Herein, we utilized the recently solved 3D structures of the melatonin receptors, in complex with the agonist 2-phenylmelatonin, ([@bib25]; [@bib42]) to perform prospective virtual ligand screening of large fragment-like compound libraries. This approach resulted in the discovery of ten new chemotypes of potent agonists, both full and partial, for MT~1~ and MT~2~. The number of sub-micromolar hits and potency of the best among them is one of the highest reported for a VLS campaign in class A GPCRs ([@bib38]) and in-line with another VLS screen for MT receptors, published while this study was in revision ([@bib43]). This is remarkable, considering that most GPCR structures have a limited capacity to distinguish agonists vs. antagonists ([@bib13]; [@bib47]) and prospective VLS campaigns often result in antagonists even when an agonist-bound VLS model is used ([@bib38]; [@bib41]).

There are several factors, related to both the VLS procedure and the intrinsic properties of the MT receptors, that likely contributed to the high hit rate and agonistic potency of the hits in our study. Thus, the high quality of the initial crystal structure, further improved by ligand-guided optimization of the pocket for VLS, has been critical for the success of our previous VLS campaigns, and likely played a similar role here ([@bib28]; [@bib34]; [@bib49]). At the same time, some intrinsic properties of MT receptors also likely facilitated successful VLS for agonists. As we mentioned above, endogenous ligand melatonin itself has unusually high picomolar potency at MT receptors (\~4 pM at MT~1~ and 50 pM at MT~2~, see [Table 1](#table1){ref-type="table"}). Melatonin and most other high-potency ligands are small (\<250 DA) and yet they still fully occupy the very small, enclosed MT pocket. Chemical space of such size-limited fragment-like libraries is much smaller than the usual drug-like space, and can be more exhaustively searched, likely resulting in higher hit rates. Moreover, most known MT receptor ligands show agonist activity, while antagonists of similar potency are notoriously hard to find, suggesting that agonists may be intrinsically preferred ligands for MT receptors ([@bib24]).

Two of the hit compounds, **37** and **62**, are MT~2~-selective partial agonists, which may have a desirable profile for eliciting antinociceptive effects mediated by melatonin receptors, and may be potentially useful in developing novel analgesics for pain management with reduced side effects ([@bib37]). Of note, while some of the newly discovered hits are selective for MT~2,~ none of the hits in this study had substantial MT~1~ selectivity. This may be explained by the lack of a bulky chemical group at the R1 position, which are known to confer strong MT~1~ selectivity, e.g. in bitopic CTL 01--05-B-A05 ligand that stretches out of the pocket via narrow side channel ([@bib42]). Design of such bitopic ligands with MT~1~ selective chemotypes would need to explore larger compounds (MW \>500), which were not considered in the current VLS screen.

This study represents a successful application of structure-based VLS to identify agonists with novel chemotypes, sub-nanomolar potencies, and a high degree of receptor subtype selectivity for a class A GPCR ([@bib38]; [@bib46]). This study also represents a successful implementation of molecular modeling and structure-based virtual screening, aimed at the melatonin receptors, facilitated by the availability of high-quality structures capturing vital ligand-receptor interactions ([@bib4]; [@bib25]; [@bib42]). Prevalence of agonists in the hit set suggests the importance of activated, agonist-bound conformations of the orthosteric pocket models for successful agonist screening. Note that, even though the receptors were thermostabilized by 9 and 8 point mutations (MT~1~/MT~2~, respectively) to aid crystallization rendering the receptor conformations inactive on the intracellular side, the agonist-bound orthosteric pockets remain relevant for structure-based drug discovery applications. Our benchmarking also corroborated the important role of ligand guided receptor optimization (LiBERO) ([@bib29]) in improving the outcomes of a structure-based VLS, similar to some of our previous VLS campaigns ([@bib34]; [@bib49]). Another critical aspect of this successful VLS is the discovery of novel chemotypes with reliable docking poses. With our screening library assembled to be fragment-like with regards to molecular weights, our hits are diverse and amenable to chemical optimization to improve their pharmacological profiles. Thus, our results also illustrate the utility of fragment-like compounds in the early stages of drug discovery.

The chemical diversity, selectivity, high potency and agonist activities of the identified hits serve as a valuable starting point for the development of tool compounds to explore the biology of melatonin receptors. With the potential for selective modulation over the melatonin receptor subtype-mediated biology, these novel chemotypes could provide new leads for the development of next-generation treatments for insomnia, pain, sleep and mood-related disorders, type 2 diabetes, and cancer.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                            Designation               Source or\                                                      Identifiers       Additional\
  (species) or\                                                      reference                                                                         information
  resource                                                                                                                                             
  ---------------------------------------- ------------------------- --------------------------------------------------------------- ----------------- ----------------------------------------------------------------------------------------------
  Cell line (*Homo sapiens*)               HTLA cells (HEKT based)   PMID:[25895059](https://www.ncbi.nlm.nih.gov/pubmed/25895059)                     

  Transfected construct (*Homo sapiens*)   MTNR1A                    PMID:[25895059](https://www.ncbi.nlm.nih.gov/pubmed/25895059)   AddGene \#66443   

  Recombinant DNA reagent, PCR primers     MTNR1A N162Q\             This paper                                                                        CTGCCGTCCTGCCGcaaCTGAGGGCAGGCAC
                                           Forward                                                                                                     

  Recombinant DNA reagent, PCR primers     MTNR1A N162Q Reverse      This paper                                                                        GTGCCTGCCCTCAGttgCGGCAGGACGGCAG

  Recombinant DNA reagent, PCR primers     MTNR1A Y281F Forward      This paper                                                                        GTTCGTAGCGAGCTtCTACATGGCTTAC

  Recombinant DNA reagent, PCR primers     MTNR1A Y281F Reverse      This paper                                                                        GTAAGCCATGTAGaAGCTCGCTACGAAC

  Commercial assay or kit                  BrightGlo Reagent         [Promega.com](https://www.promega.in/)                          Cat \# E2610      

  Chemical compound, drug                  Hit compounds             Enamine,\                                                                         See 62 compounds listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}
                                                                     Molport,\                                                                         
                                                                     Chembridge                                                                        

  Software, algorithm                      ICM-Pro,\                 [Molsof.com](https://www.molsoft.com/)                                            
                                           V3.8--7                                                                                                     

  cell line (*Homo sapiens*)               HEK293 T                  ATCC                                                            CRL-11268         

  transfected construct (*Homo sapiens*)   Human MT1                 PMID:[31019306](https://www.ncbi.nlm.nih.gov/pubmed/31019306)                     

  Chemical compound, drug                  Luciferin                 [Goldbio.com](https://www.goldbio.com/)                         Cat\#: LUCNA-1G   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Receptor model preparation and optimization {#s4-1}
-------------------------------------------

X-ray crystal structures of MT~1~ ([@bib42]) and MT~2~ ([@bib25]) receptors in complex with 2-phenylmelatonin (PDB IDs [@bib9]: 6ME3, 6ME6) were used to generate virtual screening models. Both structures were converted from PDB coordinates to ICM objects using the object conversion protocol implemented in ICM-Pro ([@bib2]). This process includes the addition of hydrogens and assignments of secondary structures, the energetically favorable protonation states to His, Asn and Gln side chains, and of formal charges to the ligand in a complex with the receptor, followed by local minimization of polar hydrogens using energy minimization protocols in ICM-Pro. The orthosteric ligand-binding pocket was further optimized with energy-based global optimization in ICM using Biased Probability Monte-Carlo (BPMC), where the orthosteric ligand and amino acid side chains within 5 Å radius were kept flexible and co-optimized ([@bib3]), as described in LiBERO protocol ([@bib29]) and its previous applications ([@bib34]; [@bib49]). To validate the models, a set of 20 known MT receptor ligands were selected from ChEMBL database ([@bib20]) along with 780 MT receptor decoys selected for each MT~1~ and MT~2~ receptor from GPCR decoy database (GDD) ([@bib19]) and docked into crystal structures, and optimized ligand models of MT receptors. Following the previously described ligand guided receptor binding pocket optimization protocol, the Receiver Operator Characteristic curves (ROC) were plotted based on the True Positive Rates (TPR) and False Positive Rates (FPR) ([@bib29]) to evaluate the model optimization. The AUC values were calculated as the areas under these ROC curves and used as a model selection criteria for prospective VLS runs. The RMSD values of ligand binding pocket side chain heavy atoms for MT~1~ and MT~2~ were 0.51 Å and 0.76 Å, respectively, compared to their corresponding crystal structures.

To perform additional evaluation of screening results with the thermostabilizing mutants in the proximity of the orthosteric site, as displayed in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, were restored to wild-type (WT) residues. The Phe residue at F251/264*^6.48^* located 4.3 Å from the ligand was mutated to Trp, followed by local minimization of side-chain conformations using energy-based sampling and minimization protocols ([@bib3]). Similarly, A104*^3.29^*, located 5.2 Å was also restored to Gly in the MT~1~ receptor model. Docking to this model suggests that these stabilizing mutations do not substantially impact the binding of known ligands and selected hit candidates into the orthosteric pocket.

Screening library {#s4-2}
-----------------

We selected a subset of commercially available (in-stock and on-demand) fragment-like compounds from the ZINC database with physicochemical properties similar to already reported melatonin receptor ligands ([@bib20]; [@bib44]). We considered compounds with molecular weight ≤250 Da and logP values ranging 1 to 5 based on the logP data of high-affinity MT ligands ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The initial dataset comprised of \~10 million compounds was converted from SMILES to 3D format, and formal charges were assigned. This set was further reduced to 8.4 million compounds after applying additional filters for net charges (between −1 to 1) and removing compounds with highly reactive functional groups and promiscuous PAINS chemotypes ('molPAINS' and 'bad groups' in ICM-Pro v.3.8--6) ([@bib6]).

Virtual ligand screening {#s4-3}
------------------------

The VLS of 8.4 million compounds library for MT~1~ and MT~2~ models were performed using the VLS protocol in ICM-Pro ([@bib1]). The receptor energy potential maps were calculated using a fine potential grid (0.5 Å). Several energy terms, including van der Waals, hydrophobic, electrostatic and hydrogen bonding interactions were considered for map calculations. Full torsional flexibility of ligands was allowed, and their internal conformational strain was considered while the receptor atoms were assigned rigid for docking. The docking was performed using BPMC conformational sampling and energy minimization protocol implemented in ICM-Pro for scoring and finding the best docking solutions at the default effort level 1. These top compounds were further docked into corresponding MT receptor models with an increased sampling effort value of 3. Each VLS run for the 8.4 million compound library used 32,000 CPU core hours on 3 Linux workstations with a total of 192 CPU cores. The chemical similarity of selected compounds was calculated using Tanimoto chemical distance function 'Distance(chem1 chem2)\', available in Molsoft's ICM-Pro ([@bib45]). The fingerprints in this function use a combination of ECFP and linear fingerprints as described in ICM-Pro manual (<http://www.molsoft.com/icm/fingerprints.html>).

Binding and functional assays {#s4-4}
-----------------------------

### Radioligand binding assays {#s4-4-1}

All compounds for in vitro testing were purchased from Enamine, Molport, and Chembridge in stock libraries, with verified identity and guaranteed purity of \>95% (37 compounds) or \>90% (25 compounds), see [Supplementary file 2](#supp2){ref-type="supplementary-material"} for compound QC data).

The Radioligand binding assays were conducted by the NIMH Psychoactive Drug Screening Program (PDSP). The NIMH PDSP is directed by Bryan L. Roth, MD, PhD, at the University of North Carolina at Chapel Hill, North Carolina, and Program Officer Jamie Driscoll at NIMH, Bethesda, MD. Binding assay procedures and protocols are also available online at <http://pdspdb.unc.edu/pdspWeb/?site=assays>. All the radioligand binding assays were performed using membranes prepared from transiently transfected HEK293T cells (purchased from ATCC, CRL-11268, authenticated by the supplier using morphology, growth characteristics, and STR profiling and certified mycoplasma-free) and in standard binding buffer (50 mM Tris, 10 mM MgCl~2~, 0.1 mM EDTA, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) as recently reported ([@bib42]). \[^3^H\]melatonin (PerkinElmer, specific activity = 77.4--84.7 Ci/mmol) is used as the radioligand. Competitive binding assays were performed with various concentrations of test compounds (100 fM to 10 µM), \[^3^H\]melatonin (0.2--1.7 nM), and MT~1~ or MT~2~ membranes in a total volume of 150 µL. Assay plates were sealed and incubated for 4 hr at 37°C in a humidified incubator until harvesting. Plates were harvested using vacuum filtration onto 0.3% polyethyleneimine pre-soaked 96-well Filtermat A (PerkinElmer) and washed three times with cold wash buffer (50 mM Tris, pH 7.4). Filters were dried and melted with a scintillation cocktail (Meltilex, PerkinElmer). Radioactivity was counted using a Wallac TriLux Microbeta counter (PerkinElmer). Results were analyzed using GraphPad Prism 7.0.

Signaling assays {#s4-5}
----------------

### G~s~ and G~i/o~-cAMP assays {#s4-5-1}

GloSensor cAMP assays were conducted according to the recently published procedure ([@bib42]) with minor modifications. Briefly, HEK293 T cells (as above) were transiently co-transfected with receptor (MT~1~ or MT~2~) and GloSensor cAMP (Promega) plasmids overnight, plated in Poly-L-Lysine coated 384-well white clear bottom plates in DMEM + 1% dialyzed FBS. Cells were used for assays at a minimum of 6 hr after plating. Culture medium was first removed and cells were stimulated with drugs in assay buffer (1x HBSS, 20 mM HEPES, 1 mg/ml BSA, 0.1 mg/ml ascorbic acid, pH 7.4) for 15 min at room temperature (this and all the following steps), followed by addition of a mixture of isoproterenol (final of 100 nM) and luciferin (final of 1 mM) for G~i/o~-cAMP production inhibition assays and luciferin (final of 1 mM) for G~s~-cAMP production assays. The plates were counted for luminescence after 25 min in a luminescence plate reader. Results were analyzed using GraphPad Prism 7.0.

Tango assays {#s4-6}
------------

Tango arrestin recruitment assays were carried out according to the previously published procedure [@bib33]. In brief, HTLA cells were transiently transfected with receptor TANGO DNA constructs overnight in DMEM with 10% FBS. Transfected cells were then plated into poly-L-Lys coated 384-well plates using DMEM supplemented with 1% dialyzed FBS. After 6 hr incubation, drug dilutions, prepared in DMEM with 1% dFBS, were added for incubation overnight (16--20 hr). Medium and drug solutions were removed, Bright-Glo reagent (20 uL/well) was added for luminescence counting 20 min later. Results were analyzed in GraphPad Prism 7.0.

Bias factors were estimated according to the published procedure [@bib30] with modifications. Briefly, normalized and pooled results were analyzed by fitting the Black and Leff operational model in Prism 7.0 to obtain Log(τ/K~A~) values for each pathway (Tango and G~i~-cAMP). Within each signaling pathway, a difference of Log(τ/K~A~), ΔLog(τ/K~A~), between a test compound and selected reference (melatonin in this case) was calculated. For a testing compound, the difference of ΔLog(τ/K~A~), ΔΔLog(τ/K~A~), was then obtained between two pathways. The bias factor is 10^ΔΔLog(τ/KA)^.
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###### Selected 62 compounds from VLS that were acquired and tested experimetnally.

The table lists vendors invormation, and Tanimo distances to the closest known MT ligands in ChEMBL database.

###### Detailed QC data for the selected 62 compounds.

Data availability {#s7}
=================

All chemical structures of candidate hits and chemical quality control information is deposited as supplementary information. All data generated and analysed during this study is included in the main manuscript or supplementary files.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The recently solved high-resolution structures of two melatonin receptors, MT~1~ and MT~2~, were used for drug discovery. These two GPCRs regulate the circadian rhythm and are well-known targets for the treatment of sleeping disorders (including temporary ones due to jetlag) and mood disorders. The structures were used for virtual screening of small molecules that could bind the receptors and modulate their activities. The results were validated first retrospectively and then also prospectively. The prospective part is particularly interesting because it included the discovery of new hits, some of which have very high activity and selectivity.

**Decision letter after peer review:**

Thank you for submitting your article \"Structure-Based Discovery of Potent and Selective Melatonin Receptor Agonists\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Nir Ben-Tal as the Reviewing Editors and Reviewer \#1, and the evaluation has been overseen by Olga Boudker as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Melatonin Receptors are GPCRs that regulate the circadian rhythm, and are used as drug targets for the treatment of sleeping disorders (including temporary ones due to jetlag) and mood disorders. Here, two recently solved crystal structures of Type-1 and 2 Melatonin Receptors (MT) were used to inform a search for more selective MT receptor agonists with novel chemotypes. Virtual ligand screening (VLS) of an 8.4 million compound set helped identifying ten new agonist chemotypes with sub-μM potency, as well as a previously not tested Melatonin derivative. Some of the compounds were selective for one receptor with the most potent new chemotype displaying thirty-fold selectivity for MT~2~ over MT~1~. Correlating the docking poses with functional assays helped investigating the structural basis of signaling bias at the receptors.

Opinion:

This is a carefully conducted and very well timed study that can be published if the issues below are properly handled.

Essential revisions:

1\) The docking and functional studies presented are thorough but there are several points that need clarification. \"Our benchmarking also underscored the critical role of structural optimization in improving the outcomes....\". What was performed is definitely not a \"structural optimization\" (see also claim in Materials and methods subsection \"Receptor Model Preparation and Optimization") of any kind, but rather structure repair. There was no optimization involved, and the criteria and mode of repair were reasonable, but arbitrary.

a\) The authors should explain in the main text if/how the changes introduced in the structure constitute an optimization rather than an arbitrary repair and opening of the ligand-binding pocket for docking. Also, the docking score for selected MT ligands appears to be better than -32 kJ/mol -- is that a well-recognized criterion? It seems like an arbitrary number that should be put in the context of, maybe, the docking score of Melatonin.

b\) It is quite remarkable that an initial screen yields compounds with such high affinities/potencies: Several compounds were obtained with double-digit nanomolar potencies -- properties usually only achieved after several rounds of optimization. Related to that is also the unusual observation that all ligands appear to be agonists -- a fact which the authors acknowledge. However, the authors should significantly elaborate on why they think their screen was so successful (in terms of initial hits and compound pharmacology), which would be very valuable to the field of structure-based drug discovery in general.

2\) The authors use two different functional assays to test compound activity in two different pathways. However, it isn\'t always clear which assay/pathway is discussed when the authors list potencies in the main text (particularly in the \"Structural basis of Subtype Selectivity of the Hits\" section). Also, the G protein signaling assay does not appear to be receptor selective. While it may not be necessary to show these results, what kinds of controls did the authors use in the assay to make sure their response is MT receptor mediated?

3\) The authors also investigate the functional selectivity of e.g. compound 37, which shows no G-protein mediated signaling but activates ß-arrestin signaling at MT~1~. The authors suggest that this observation is due to the absence of a hydrogen-bond with N162(4.60) and further conclude that Y281/294(7.38) plays a key role in arresting signaling. However, these suggestions appear speculative and solely rely on the accuracy of the docking pose and previous crystal structures of non-related chemotypes. Instead, the authors need to test structure-guided mutants (e.g. N162Q, Y281F, and others) to examine their hypotheses.

4\) The work represents successful use of VLS in laying the groundwork for more selective and potent agonists for MT~1~ and MT~2~. The writing is generally clear and carries the reader through the authors\' thoughts and experiments in a logical progression. If anything, the writing is too lean at points. The authors highlight the relevance of the study in the Introduction and Discussion but do not explain the functional differences between MT~1~ and MT~2~. A brief explanation of the role each receptor plays in different biological processes would provide a better context for their intended goal. In addition, how the authors intend to use these results to inform future studies is not clear. What aspects of MT biology/pharmacology do the authors plan to explore? The last sentence of the Discussion just seems like a list of everything Melatonin-related.

5\) With drug discovery, aggregation of the putative hits is always a concern. Brian Shoichet wrote a lot about that. It is less likely to be an issue here, e.g., because of the specificity of some of the hits, but we never know. The authors should test that, least for the main hit compounds.

6\) It is unclear how close the thermostabilizing mutations are to the binding site (G104A and F251W in MT~1~ or F264W in MT~2~). The authors should highlight these residues in one of the figures and refer to this figure in the relevant places in the text. Because they affect the docking scores it is important to visualize their location relative to the binding site and discuss this in light of point 1a.

7\) \"To our knowledge, this study represents one of the few cases of successful VLS to identify agonists with novel chemotypes,...... and a high degree of receptor subtype selectivity for a class A GPCR\". This is a rather complex claim for a first, since it involves a specific combination of approaches that are commonly used. The success of the combination can be pointed out, but as always, priority claims are tedious. This may not diminish the importance of the compounds, but it is hardly a trailblazer or surprise of any kind. This should be modified or eliminated.

8\) \"Thus, it also proves the utility of fragment-like compounds in the early stages of drug discovery.\" It is not clear why such \"proof\" was needed, as this is an option in screening because it is considered useful. In any case it can only be a demonstration of successful use, not a proof of anything.

10.7554/eLife.53779.sa2

Author response

> Essential revisions:1) The docking and functional studies presented are thorough but there are several points that need clarification. \"Our benchmarking also underscored the critical role of structural optimization in improving the outcomes....\". What was performed is definitely not a \"structural optimization\" (see also claim in Materials and methods subsection \"Receptor Model Preparation and Optimization") of any kind, but rather structure repair. There was no optimization involved, and the criteria and mode of repair were reasonable, but arbitrary.a) The authors should explain in the main text if/how the changes introduced in the structure constitute an optimization rather than an arbitrary repair and opening of the ligand-binding pocket for docking.

Thank you for pointing to this inaccuracy. In this study we followed our previously published protocol for ligand-guided receptor optimization, "LiBERO" (Katritch et al., 2012). The protocol involves conformational optimization of the pocket side chains and selecting the best resulting conformers in a small scale VLS benchmark with known ligands. Like in several previous examples, this protocol introduces only minor changes in side chain conformation of the receptor binding pocket, resulting in optimized model performance for VLS, as reflected in improved ROC curves shown Figure 1E. Accordingly, we replaced "receptor structural optimization" with more accurate *"ligand guided optimization"* and added the relevant references to the LiBERO method and previous applications of this protocol.

> Also, the docking score for selected MT ligands appears to be better than -32 kJ/mol -- is that a well-recognized criterion? It seems like an arbitrary number that should be put in the context of, maybe, the docking score of Melatonin.

The value -32 kJ/mol is a standard cutoff value for VLS in ICM, though we agree that it can vary dramatically between receptors, and thus requires further explanation. Here, we introduced the comparative value of these scores by adding the following text: "these scores are better or comparable with the dock score of melatonin (-29.3) and other high affinity ligands of MT receptors".

> b\) It is quite remarkable that an initial screen yields compounds with such high affinities/potencies: Several compounds were obtained with double-digit nanomolar potencies -- properties usually only achieved after several rounds of optimization. Related to that is also the unusual observation that all ligands appear to be agonists -- a fact which the authors acknowledge. However, the authors should significantly elaborate on why they think their screen was so successful (in terms of initial hits and compound pharmacology), which would be very valuable to the field of structure-based drug discovery in general.

We agree that this point requires additional discussion. There are several factors related to both VLS procedure and intrinsic properties of the MT receptor that likely contributed to the high hit rate and agonistic potency of hits. As already mentioned, the high quality of the initial crystal structure, further improved by ligand-guided optimization of the pocket for VLS was important for the success of the screening. Some intrinsic properties of MT receptors also may have contributed to very high potency of hits, for example endogenous ligand melatonin already has exceptionally high potency in single pM range. Melatonin and the other high-potency ligands are small (\<250 DA) as they fit small and enclosed MT pocket. Chemical space of such size-limited fragment like libraries is much smaller than usual drug-like space, and can be more exhaustively searched, resulting in better ligands. Regarding agonism preference -- yes, most of the known MT receptor ligands are agonists, while antagonists of similar potency are notoriously hard to find, suggesting that agonists are intrinsically preferred ligands for MT receptors. The Discussion section was updated accordingly with these explanations.

> 2\) The authors use two different functional assays to test compound activity in two different pathways. However, it isn\'t always clear which assay/pathway is discussed when the authors list potencies in the main text (particularly in the \"Structural basis of Subtype Selectivity of the Hits\" section). Also, the G protein signaling assay does not appear to be receptor selective. While it may not be necessary to show these results, what kinds of controls did the authors use in the assay to make sure their response is MT receptor mediated?

We used in the Gi mediated cAMP inhibition assays in "Structural basis of Subtype Selectivity of Hits", and updated the text of this section accordingly.

We thank the reviewer for pointing this out. In the G~i/o~-mediated cAMP production inhibition assays with HEK293T cells transiently transfected with MT~1~ or MT~2~ receptor, we also carried out assays at control cells -- HEK293T cells without transfections of either MT~1~ or MT~2~ for potential nonspecific activity or activity at endogenous G~i/o~-coupled GPCRs. We didn't observe any activity at control cells. We have updated the text and specifically stated the observation in Figure 3 legend.

> 3\) The authors also investigate the functional selectivity of e.g. compound 37, which shows no G-protein mediated signaling but activates ß-arrestin signaling at MT1. The authors suggest that this observation is due to the absence of a hydrogen-bond with N162(4.60) and further conclude that Y281/294(7.38) plays a key role in arresting signaling. However, these suggestions appear speculative and solely rely on the accuracy of the docking pose and previous crystal structures of non-related chemotypes. Instead, the authors need to test structure-guided mutants (e.g. N162Q, Y281F, and others) to examine their hypotheses.

We performed functional assays on MT~1~ mutants and showed that compound 37 potency in receptor slightly improved with N162Q mutation, while strongly reduced with Y281F mutation (see Figure 6---figure supplement 1). For comparison, compound 28 drastically (\>100-fold) reduced potency in MT~1~ mutants N162Q and Y281F. This new experimental data support our hypothesis that G-protein biased comp 37 lacks a hydrogen bond with N162. We added corresponding text and Figure 6---figure supplement 1.

> 4\) The work represents successful use of VLS in laying the groundwork for more selective and potent agonists for MT1 and MT2. The writing is generally clear and carries the reader through the authors\' thoughts and experiments in a logical progression. If anything, the writing is too lean at points. The authors highlight the relevance of the study in the Introduction and Discussion but do not explain the functional differences between MT1 and MT2. A brief explanation of the role each receptor plays in different biological processes would provide a better context for their intended goal. In addition, how the authors intend to use these results to inform future studies is not clear. What aspects of MT biology/pharmacology do the authors plan to explore? The last sentence of the Discussion just seems like a list of everything Melatonin-related.

We thank the reviewer for the suggestion and agree with the notion that MT subtype mediated biology/pharmacology is and will be an important avenue to explore, perhaps with the aid of highly selective MT ligands. We have added/updated the Introduction and Discussion text.

> 5\) With drug discovery, aggregation of the putative hits is always a concern. Brian Shoichet wrote a lot about that. It is less likely to be an issue here, e.g., because of the specificity of some of the hits, but we never know. The authors should test that, least for the main hit compounds.

We agree that ligand non-selective binding and aggregation are the major concerns affecting the validity of the binding and functional assays. To address this concern, we performed off target binding experiments for selected hits (compounds 21, 28 and 37) on a large panel of 47 GPCRs, ion-channels and transporters, and included the results as a new paragraph in text and Figure 6---figure supplement 1. These results indicate that potential aggregation of hits is not a concern for these ligands. Moreover, the result suggest that our top hits may have selectivity towards MT receptors on whole proteome scale, further validating them as new chemical probes.

> 6\) It is unclear how close the thermostabilizing mutations are to the binding site (G104A and F251W in MT1 or F264W in MT2). The authors should highlight these residues in one of the figures and refer to this figure in the relevant places in the text. Because they affect the docking scores it is important to visualize their location relative to the binding site and discuss this in light of point 1a.

The illustration of position of the residues and distances to them are added as Figure 6---figure supplement 2, with corresponding mentions in the main text on p 22. G104A is more than 5 A away and should not make any difference for binding ligand. Similarly, the closest distance for F6.48 residue is 4.3A between hydrophobic residue or receptor and polar amide of the ligand, suggesting lack of significant contact.

> 7\) \"To our knowledge, this study represents one of the few cases of successful VLS to identify agonists with novel chemotypes,...... and a high degree of receptor subtype selectivity for a class A GPCR\". This is a rather complex claim for a first, since it involves a specific combination of approaches that are commonly used. The success of the combination can be pointed out, but as always, priority claims are tedious. This may not diminish the importance of the compounds, but it is hardly a trailblazer or surprise of any kind. This should be modified or eliminated.

We agree that such comparison with previous VLS studies are not very adequate here, especially across different receptors (see also answer to comment 1b above), so we removed it.

> 8\) \"Thus, it also proves the utility of fragment-like compounds in the early stages of drug discovery.\" It is not clear why such \"proof\" was needed, as this is an option in screening because it is considered useful. In any case it can only be a demonstration of successful use, not a proof of anything.

We agree with the reviewers and modified the text accordingly to remove statements of "proof" and "validation" form Discussion.

[^1]: Discovery Chemistry, Genentech Inc, South San Francisco, United States.

[^2]: Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, United States.
